Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 4/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21272212 | 1.00 | CCKBR (0.77) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL21272182 | 0.91 | CHRM1 (0.77) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL21272180 | 0.91 | CHRM1 (0.77) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL10203612 | 0.88 | CCKBR (0.61) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL11772245 | 0.88 | CCKBR (0.73) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL782955 | 0.88 | CCKBR (0.73) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL21272204 | 0.87 | CCKBR (1.00) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL11770649 | 0.87 | CCKBR (0.72) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL9526063 | 0.87 | CCKBR (1.00) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL11822552 | 0.87 | CCKBR (1.00) | CCKBRCHRM1MEN1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021448-B2 | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases | HOFFMANN-LA ROCHE INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021448-B2 | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases | HOFFMANN-LA ROCHE INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3535253-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
| US-20190256478-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190256478-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021448-B2 | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases | CHRM1, CHRM2, CHRM4 | CCKBR 1083/4885CHRM1 1/4885MEN1 3220/4885 |
| US-20190256478-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | CHRM1, CHRM2, CHRM4 | CCKBR 1083/4885CHRM1 1/4885MEN1 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.